Gyros launches new product to support cell & gene therapy manufacturing

By The Science Advisory Board staff writers

September 2, 2020 -- Gyros Protein Technologies introduced a new product, Gyrolab AAVX titer kit, for adeno-associated virus (AAV) vector titer determination in AAV vector manufacturing.

Gyrolab AAVX is a miniaturized immunoassay that provides critical quality attributes of the U.S. Food and Drug Administration (FDA) process validation guidelines. It has broad applicability across numerous AAV serotypes (AAV1, AAV8, AAVrh10).

The ready-to-use product will support scientists in the development and production of cell and gene therapies to reduce the time needed to produce treatments. The kit generates results four times faster and requires 10 times less sample compared to traditional enzyme-linked immunosorbent assay (ELISA) methods, according to the company.

Gyrolab AAVX is based on the highly selective AAVX affinity ligand developed with Thermo Fisher Scientific's CaptureSelect technology. The ligands are the basis of Thermo Fisher's Poros CaptureSelect AAVX affinity resin, which is frequently used to purify AAV viral vectors.

Gyros immunoassay integrated into TJU training programs
Immunoassay developer Gyros Protein Technologies announced on March 17 that it will integrate its technology into advanced training programs at the Jefferson...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter